Integrating the commercialization continuum.
DMC is a boutique commercialization and revenue platform for advanced diagnostics. We integrate the fragmented pathway between a promising innovation and sustainable reimbursed revenue.
Great science is only the beginning.
A promising assay can succeed scientifically and still stall commercially.
The path from scientific readiness to payment runs through analytical validation, coding strategy, evidence development, payer coverage, reimbursement, market launch, physician adoption, claims, denials, appeals, and collections. Each stage is a distinct discipline with distinct stakeholders, and every handoff between them costs time, context, and margin.
Validation ≠ Coding ≠ Coverage ≠ Reimbursement ≠ Collections. DMC's value is integrating those distinct stages under senior accountability.
- Senior expertise, directly engaged.
- Built for diagnostics that do not fit neatly into a standard playbook.
- Selective partnerships for complex commercialization and reimbursement challenges.
Five integrated stages around the economic life of an assay.
How the model works, stage by stage. Full detail on each discipline sits on the capabilities page.
- 01 — Assay
Assay Readiness & Validation
Preparing the science, documentation, and gaps so the assay is genuinely ready to commercialize. - 02 — Code
Coding & Reimbursement Strategy
Choosing the coding pathway and building the evidence behind payment. A code is not coverage, and coverage is not payment — we plan for all three separately. - 03 — Cover
Coverage & Market Access
Payer strategy, evidence requirements, and coverage planning sequenced ahead of launch, not after it. - 04 — Commercialize
Commercialization & Adoption
Go-to-market, physician adoption, and health-system contracting aligned to the reimbursement plan already in place. - 05 — Collect
Revenue Cycle & Collections
Specialized laboratory RCM informed by the scientific and reimbursement context behind each claim.
One assay can become a much larger relationship.
DMC can enter through a difficult new diagnostic program, prove value across reimbursement and commercialization, and expand into additional assays and broader laboratory revenue-cycle support.
DMC brings novel-assay companies into a broader laboratory and revenue-cycle ecosystem — and identifies additional commercialization opportunities inside existing laboratory relationships. The result is an expanding strategic relationship rather than a series of one-off projects.
Selective engagements. Senior people. Commercial outcomes.
We take on a limited number of engagements so that the people who scope the work are the people who do it. Value is measured in stronger collections, reduced friction, better reimbursement execution, lower administrative burden, and commercialization outcomes that hold up over time.
See capabilities